TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06883526: A Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Phase I/II Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma

Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 60 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT06883526 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06883526 Rescue Dossier →